Dabrafenib + Trametinib Improve Overall Response Rates in Pediatric Patients with Low-Grade Gliomas

The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas.

Read more: https://ascopost.com/news/june-2022/dabrafenib-plus-trametinib-improve-overall-response-rates-vs-standard-of-care-chemotherapy-in-pediatric-patients-with-low-grade-gliomas/